Injectable Anticoagulants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Injectable Anticoagulants Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

  • Transparency Market Research
  • Ongoing
  • Healthcare

Report Description

Anticoagulants help control the adhering of platelets and stop clotting proteins from binding together. These are commonly used in the prevention and treatment of venous thrombosis, pulmonary embolism, and other conditions of blood clotting. Injectable anticoagulants are administered via different routes of injectable drug delivery and are categorized into direct thrombin inhibitors, factor Xa inhibitors, heparins, low-molecular-weight heparin (LMWH) including dalteparin, enoxaparin, and others. Heparin is an injectable anticoagulant widely used in hospitals for rapid anticoagulation. LMWHs are highly acceptable and preferred over heparins, as LMWHs can be self-administered when used in home settings, while heparins are large sized molecules and bleeding is associated with its use. Hence, these can only be injected at hospitals through skilled professionals.

According to the World Health Organization (WHO), prolonged traveling by passengers via automobile, train, or airplane for more than four hours increases the risk of developing venous thromboembolism. Coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, affect nearly 1 million people in the U.S. each year. According to the Centers for Disease Control and Prevention, 500,000 to 900,000 people in the U.S. are affected by VTE each year. A study published by Deutsches Arzteblatt International in 2013 revealed that the annual incidence rate of diagnosed VTE in Germany stood at 150 to 200 cases per 100,000. The statistics above clearly indicate the demand for safe, reliable, and affordable anticoagulants.

Rise in incidence of coagulation and renal and heart diseases, commercialization of safe and cost-effective biological origin anti-coagulants, enhanced quality control measures, increase in geriatric population, and surge in investment in research and development of biological origin drugs drive the market. High cost of treatment is the only factor restraining the market.

The global injectable anticoagulants market can be segmented based on drug type, application, and distribution channel. In terms of drug type, the market can be categorized into low-molecular-weight heparin (LMWH) and direct thrombin inhibitors (DTI). The low-molecular-weight heparin segment accounted for the largest market share and is expected to witness rapid growth during the forecast period. Based on application, the injectable anticoagulants market can be classified into venous thromboembolism (VTE), atrial fibrillation, acute coronary syndrome, and myocardial infarction. In terms of distribution channel, the global market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share and the trend is likely to continue during the forecast period owing to rise in prevalence of deep vein thrombosis and increase in hospital inpatients for different disease treatments. This, in turn, is likely to drive the global injectable anticoagulants market during the forecast period.

Geographically, the global injectable anticoagulants market can be segmented into five major regions: North America, Middle East & Africa, Latin America, Asia Pacific, and Europe. North America is the leading market for injectable anticoagulants in terms of revenue, followed by Europe. The U.S. held the largest share of the market in North America, followed by Canada. The injectable anticoagulants market in Asia Pacific is likely to expand at a high CAGR during the forecast period. This is attributed to increase in patient population and rise in incidence of chronic diseases, which has led to high demand for injectable anticoagulant products.

Key players operating in the global injectable anticoagulants market include Sanofi, Genentech (Roche), Boehringer Ingelheim, Pfizer, The Medicines Company, B. Braun Melsungen AG, Baxter, Aspen Otsuka, Fresenius SE & Co. KGaA, LEO Pharma A/S, and Sagent Pharmaceuticals, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis. 

Have query on this report?

Make an Enquiry

Success Stories

Our Clients